In the absence of agreement within the coordination group, the Community arbitration procedure provided for in articles 32 to 34 of Directive 2001/83/EC of the European Parliament and of the Council applies. Where France is the reference State, the Director General of the Agence nationale de sécurité du médicament et des produits de santé is responsible for initiating this procedure by informing the European Medicines Agency of the disagreement.
The Director General of the Agency grants, refuses, varies or withdraws the marketing authorisation for the medicinal product concerned in accordance with the decision taken by the European Commission at the end of this procedure within a period of thirty days.
Pending the decision of the European Commission, the Director General of the Agency may, at the request of the applicant, grant a marketing authorisation. Once this decision has been taken, the authorisation may, if necessary, be varied or withdrawn in accordance with the conditions set out in the previous paragraph.